TransThera Sciences (Nanjing). Inc.
2617.HK
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.14B
Close$
$1.25
86.6% downside
Current Fair Value
86.6% downsideOvervalued by 86.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $4.14 Billion |
|---|---|
| Enterprise Value | $3.72 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.76 |
| Beta | 3.09 |
| Outstanding Shares | 401,513,627 |
Return
| Return on Equity | -30.56% |
|---|---|
| Return on Assets | -27.18% |
| Return on Invested Capital | -30.87% |
Valuation & Multiples
| P/E Ratio | -8.62 |
|---|---|
| PEG | 38.02 |
| Price to Sales | - |
| Price to Book Ratio | 4.64 |
| Enterprise Value to Revenue | 106.39 |
| Enterprise Value to EBIT | -13.68 |
| Enterprise Value to Net Income | -14 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About TransThera Sciences (Nanjing). Inc.
132 employees
CEO: Yong Qian Wu TransThera Sciences (Nanjing), Inc., clinical stage biopharmaceutical company, discovers, develops, and commercializes small molecule therapies for oncology, inflammatory, and cardiometabolic diseases. The company provides Tinengotinib (...